196 related articles for article (PubMed ID: 31826986)
1. Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF.
Möhn N; Pfeuffer S; Ruck T; Gross CC; Skripuletz T; Klotz L; Wiendl H; Stangel M; Meuth SG
Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 31826986
[TBL] [Abstract][Full Text] [Related]
2. Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
Arroyo R; Bury DP; Guo JD; Margolin DH; Melanson M; Daizadeh N; Cella D
Mult Scler; 2020 Jul; 26(8):955-963. PubMed ID: 31144568
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.
Wiendl H; Carraro M; Comi G; Izquierdo G; Kim HJ; Sharrack B; Tornatore C; Daizadeh N; Chung L; Jacobs AK; Hogan RJ; Wychowski LV; Van Wijmeersch B;
Neurol Neuroimmunol Neuroinflamm; 2020 Jan; 7(1):. PubMed ID: 31662412
[TBL] [Abstract][Full Text] [Related]
4. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
[TBL] [Abstract][Full Text] [Related]
5. Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis: Α case series.
Notas K; Papadaki E; Orologas A; Moschou M; Kimiskidis VK
Mult Scler Relat Disord; 2020 Feb; 38():101517. PubMed ID: 31751858
[TBL] [Abstract][Full Text] [Related]
6. Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Cuker A; Bass AD; Nadj C; Agius MA; Steingo B; Selmaj KW; Thoits T; Guerreiro A; Van Wijmeersch B; Ziemssen T; Meuth SG; LaGanke CC; Thangavelu K; Rodriguez CE; Baker DP; Margolin DH; Jannsens A
Mult Scler; 2020 Jan; 26(1):48-56. PubMed ID: 30785358
[TBL] [Abstract][Full Text] [Related]
7. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
[TBL] [Abstract][Full Text] [Related]
8. IgM to S-nitrosylated protein is found intrathecally in relapsing-remitting multiple sclerosis.
Hvaring C; Vujicic S; Aasly JO; Feinstein DL; White LR; Boullerne AI
J Neuroimmunol; 2013 Mar; 256(1-2):77-83. PubMed ID: 23351705
[TBL] [Abstract][Full Text] [Related]
9. Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis.
Kashani N; Kelland EE; Vajdi B; Anderson LM; Gilmore W; Lund BT
Front Immunol; 2021; 12():706278. PubMed ID: 34777337
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.
Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
Mult Scler; 2020 May; 26(6):659-667. PubMed ID: 30912689
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.
Hartung HP; Aktas O; Boyko AN
Mult Scler; 2015 Jan; 21(1):22-34. PubMed ID: 25344374
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.
Frau J; Coghe G; Lorefice L; Fenu G; Musu L; Cocco E
J Neurol; 2019 Jun; 266(6):1405-1411. PubMed ID: 30863891
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Perumal JS; Foo F; Cook P; Khan O
Mult Scler; 2012 Aug; 18(8):1197-9. PubMed ID: 22252465
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis.
Syed YY
Drugs; 2021 Jan; 81(1):157-168. PubMed ID: 33367970
[TBL] [Abstract][Full Text] [Related]
16. Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy.
Meltzer E; Campbell S; Ehrenfeld B; Cruz RA; Steinman L; Parsons MS; Zamvil SS; Frohman EM; Frohman TC
Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32769201
[TBL] [Abstract][Full Text] [Related]
17. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
Frau J; Saccà F; Signori A; Baroncini D; Fenu G; Annovazzi P; Capobianco M; Signoriello E; Laroni A; La Gioia S; Sartori A; Maniscalco GT; Bonavita S; Clerico M; Russo CV; Gallo A; Lapucci C; Carotenuto A; Sormani MP; Cocco E;
J Neurol; 2019 Oct; 266(10):2440-2446. PubMed ID: 31209573
[TBL] [Abstract][Full Text] [Related]
18. Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis.
Keller CW; Ruck T; McHugh D; Pfeuffer S; Gross CC; Korsukewitz C; Melzer N; Klotz L; Meuth SG; Münz C; Nimmerjahn F; Wiendl H; Lünemann JD
Ann Clin Transl Neurol; 2019 Dec; 6(12):2586-2594. PubMed ID: 31682087
[TBL] [Abstract][Full Text] [Related]
19. Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.
Sisay S; Lopez-Lozano L; Mickunas M; Quiroga-Fernández A; Palace J; Warnes G; Alvarez-Lafuente R; Dua P; Meier UC
J Neuroimmunol; 2017 May; 306():40-45. PubMed ID: 28385186
[TBL] [Abstract][Full Text] [Related]
20. IgG4-related autoimmune manifestations in Alemtuzumab-treated multiple sclerosis patients.
Vakrakou AG; Tzanetakos D; Evangelopoulos ME; Fragoulis GE; Kazakou P; Lekka E; Kafasi N; Tzartos JS; Andreadou E; Koutsis G; Gialafos E; Dimitrakopoulos A; Zampeli E; Rontogianni D; Theocharis S; Zapanti E; Stathopoulos PA; Anagnostouli M; Stefanis L; Kilidireas C
J Neuroimmunol; 2021 Dec; 361():577759. PubMed ID: 34742035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
